Actemra: payments to doctors
Payments that named Actemra as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $22M
- Providers
- 4,886
- Transactions
- 29,240
- Average per transaction
- $754
The per-transaction average — $754 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,886 providers the average total is $4,511, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $20,691,994 | 93.9% |
| Genentech USA, Inc. | $1,100,370 | 5.0% |
| F. Hoffmann-la Roche AG | $214,351 | 1.0% |
| Hoffmann-la Roche Limited | $15,713 | 0.1% |
| Roche Products Limited | $13,844 | 0.1% |
| Chugai Pharmaceutical Co., Ltd. | $3,640 | 0.0% |